{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:00:25Z","timestamp":1787763625021,"version":"build-2784847793"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Grants-in-Aid for Early-Career Scientists","award":["22K15426"],"award-info":[{"award-number":["22K15426"]}]},{"DOI":"10.13039\/501100001691","name":"Grants-in-Aid for Scientific Research","doi-asserted-by":"crossref","award":["24K11570"],"award-info":[{"award-number":["24K11570"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nippon Shinyaku Research Grant"},{"DOI":"10.13039\/501100003837","name":"Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grant-in-Aid for Challenging Research","award":["21K19900"],"award-info":[{"award-number":["21K19900"]}]},{"name":"Grant-in-Aid for Scientific Research","award":["22H02918"],"award-info":[{"award-number":["22H02918"]}]},{"name":"Grants-in-Aid from the Japan Agency for Medical Research and Development","award":["21ae0101074h0001"],"award-info":[{"award-number":["21ae0101074h0001"]}]},{"name":"Grants-in-Aid from the Japan Agency for Medical Research and Development","award":["22ae0101074h0001"],"award-info":[{"award-number":["22ae0101074h0001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12185-024-03880-3","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T19:19:14Z","timestamp":1732562354000},"page":"206-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia\/lymphoma"],"prefix":"10.1007","volume":"121","author":[{"given":"Yuma","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morishige","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiji","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yonekura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"3880_CR1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481\u201392.","journal-title":"Blood"},{"key":"3880_CR2","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","volume":"15","author":"K Ishitsuka","year":"2014","unstructured":"Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517\u201326.","journal-title":"Lancet Oncol"},{"key":"3880_CR3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984\u20131987). Br J Haematol. 1991;79:428\u201337.","journal-title":"Br J Haematol"},{"key":"3880_CR4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015;47:1304\u201315.","journal-title":"Nat Genet"},{"key":"3880_CR5","doi-asserted-by":"crossref","first-page":"16619","DOI":"10.1073\/pnas.1010722107","volume":"107","author":"J Pancewicz","year":"2010","unstructured":"Pancewicz J, Taylor JM, Datta A, Baydoun HH, Waldmann TA, Hermine O, et al. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci U S A. 2010;107:16619\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3880_CR6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12943-018-0857-2","volume":"17","author":"CH Yeh","year":"2018","unstructured":"Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018;17:115.","journal-title":"Mol Cancer"},{"key":"3880_CR7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccr.2014.02.018","volume":"25","author":"P Ntziachristos","year":"2014","unstructured":"Ntziachristos P, Lim JS, Sage J, Aifantis I. From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell. 2014;25:318\u201334.","journal-title":"Cancer Cell"},{"key":"3880_CR8","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1158\/0008-5472.CAN-06-4381","volume":"67","author":"A Malyukova","year":"2007","unstructured":"Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M, et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 2007;67:5611\u20136.","journal-title":"Cancer Res"},{"key":"3880_CR9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1084\/jem.20070876","volume":"204","author":"J O'Neil","year":"2007","unstructured":"O\u2019Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204:1813\u201324.","journal-title":"J Exp Med"},{"key":"3880_CR10","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1073\/pnas.1601537113","volume":"113","author":"CH Yeh","year":"2016","unstructured":"Yeh CH, Bellon M, Pancewicz-Wojtkiewicz J, Nicot C. Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. Proc Natl Acad Sci U S A. 2016;113:6731\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3880_CR11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.17749","volume":"195","author":"Y Sakamoto","year":"2021","unstructured":"Sakamoto Y, Ishida T, Masaki A, Murase T, Takeshita M, Muto R, et al. Clinical significance of TP53 mutations in adult T-cell leukemia\/lymphoma. Br J Haematol. 2021;195:571\u201384.","journal-title":"Br J Haematol"},{"key":"3880_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.17211","volume":"192","author":"Y Sakamoto","year":"2021","unstructured":"Sakamoto Y, Ishida T, Masaki A, Takeshita M, Iwasaki H, Yonekura K, et al. Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia\/lymphoma. Br J Haematol. 2021;192:281\u201391.","journal-title":"Br J Haematol"},{"key":"3880_CR13","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","volume":"132","author":"Y Sakamoto","year":"2018","unstructured":"Sakamoto Y, Ishida T, Masaki A, Murase T, Yonekura K, Tashiro Y, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment. Blood. 2018;132:758\u201361.","journal-title":"Blood"},{"key":"3880_CR14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/hon.3072","volume":"40","author":"Y Sakamoto","year":"2022","unstructured":"Sakamoto Y, Ishida T, Masaki A, Murase T, Ohtsuka E, Takeshita M, et al. CCR7 alterations associated with inferior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment. Hematol Oncol. 2022;40:876\u201384.","journal-title":"Hematol Oncol"},{"key":"3880_CR15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","volume":"113","author":"Y Yamada","year":"2001","unstructured":"Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375\u201382.","journal-title":"Br J Haematol"},{"key":"3880_CR16","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","volume":"25","author":"K Tsukasaki","year":"2007","unstructured":"Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458\u201364.","journal-title":"J Clin Oncol"},{"key":"3880_CR17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","volume":"16","author":"T Ishii","year":"2010","unstructured":"Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2010;16:1520\u201331.","journal-title":"Clin Cancer Res"},{"key":"3880_CR18","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","volume":"120","author":"T Ishida","year":"2012","unstructured":"Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734\u201341.","journal-title":"Blood"},{"key":"3880_CR19","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.bbmt.2013.09.014","volume":"19","author":"T Ishida","year":"2013","unstructured":"Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Takatsuka Y, et al. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study. Biol Blood Marrow Transplant. 2013;19:1731\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3880_CR20","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3389\/fmicb.2019.02235","volume":"10","author":"A Utsunomiya","year":"2019","unstructured":"Utsunomiya A. Progress in allogeneic hematopoietic cell transplantation in adult T-cell leukemia-lymphoma. Front Microbiol. 2019;10:2235.","journal-title":"Front Microbiol"},{"key":"3880_CR21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","volume":"37","author":"LB Cook","year":"2019","unstructured":"Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37:677\u201387.","journal-title":"J Clin Oncol"},{"key":"3880_CR22","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-ccr4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34:3426\u201333.","journal-title":"J Clin Oncol"},{"key":"3880_CR23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15123","volume":"184","author":"T Ishida","year":"2019","unstructured":"Ishida T, Jo T, Takemoto S, Suzumiya H, Suehiro Y, Choi I, et al. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2019;184:479\u201383.","journal-title":"Br J Haematol"},{"key":"3880_CR24","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1182\/bloodadvances.2020003053","volume":"4","author":"K Yonekura","year":"2020","unstructured":"Yonekura K, Kusumoto S, Choi I, Nakano N, Ito A, Suehiro Y, et al. Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study. Blood Adv. 2020;4:5133\u201345.","journal-title":"Blood Adv"},{"key":"3880_CR25","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","volume":"34","author":"T Ishida","year":"2016","unstructured":"Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002. J Clin Oncol. 2016;34:4086\u201393.","journal-title":"J Clin Oncol"},{"issue":"10168","key":"3880_CR26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340.","journal-title":"Lancet"},{"key":"3880_CR27","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/cas.15431","volume":"113","author":"A Utsunomiya","year":"2022","unstructured":"Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: phase IIb results. Cancer Sci. 2022;113:2778\u201387.","journal-title":"Cancer Sci"},{"issue":"10","key":"3880_CR28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, et al. An open-label, single-arm, phase 2 trial of valemetostat in relapsed or refractory adult T-cell leukemia\/lymphoma. Blood. 2023;141(10):1159\u201368.","journal-title":"Blood"},{"key":"3880_CR29","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.3324\/haematol.2022.281510","volume":"10","author":"T Kameda","year":"2023","unstructured":"Kameda T, Kataoka K, Kamiunten A, Hidaka M, Miyoshi H, Nakano N, et al. Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia\/lymphoma. Haematologica. 2023;10:2178\u201391.","journal-title":"Haematologica"},{"issue":"10","key":"3880_CR30","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3324\/haematol.2009.012047","volume":"94","author":"CG Mullighan","year":"2009","unstructured":"Mullighan CG. Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia. Haematologica. 2009;94(10):1338\u201340.","journal-title":"Haematologica"},{"key":"3880_CR31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc1880","volume":"6","author":"C Grabher","year":"2006","unstructured":"Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006;6:347\u201359.","journal-title":"Nat Rev Cancer"},{"key":"3880_CR32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","volume":"306","author":"AP Weng","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W, Morris JP 4th, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269\u201371.","journal-title":"Science"},{"key":"3880_CR33","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1182\/blood-2008-08-174748","volume":"113","author":"WR Gordon","year":"2009","unstructured":"Gordon WR, Roy M, Vardar-Ulu D, Garfinkel M, Mansour MR, Aster JC, et al. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood. 2009;113:4381\u201390.","journal-title":"Blood"},{"key":"3880_CR34","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1101\/gad.1621808","volume":"22","author":"S Matsuoka","year":"2008","unstructured":"Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev. 2008;22:986\u201391.","journal-title":"Genes Dev"},{"key":"3880_CR35","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1084\/jem.20062299","volume":"204","author":"I Onoyama","year":"2007","unstructured":"Onoyama I, Tsunematsu R, Matsumoto A, Kimura T, de Albor\u00e1n IM, Nakayama K, et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med. 2007;204:2875\u201388.","journal-title":"J Exp Med"},{"key":"3880_CR36","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/PAS.0000000000000871","volume":"41","author":"Y Mihashi","year":"2017","unstructured":"Mihashi Y, Mizoguchi M, Takamatsu Y, Ishitsuka K, Iwasaki H, Koga M, et al. C-MYC and its main ubiquitin ligase, FBXW7, influence cell proliferation and prognosis in adult T-cell leukemia\/lymphoma. Am J Surg Pathol. 2017;41:1139\u201349.","journal-title":"Am J Surg Pathol"},{"key":"3880_CR37","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","volume":"30","author":"H Katsuya","year":"2012","unstructured":"Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol. 2012;30:1635\u201340.","journal-title":"J Clin Oncol"},{"key":"3880_CR38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.12962","volume":"166","author":"T Fukushima","year":"2014","unstructured":"Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014;166:739\u201348.","journal-title":"Br J Haematol"},{"key":"3880_CR39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"20","author":"AJ Levine","year":"2020","unstructured":"Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 2020;20:471\u201380.","journal-title":"Nat Rev Cancer"},{"key":"3880_CR40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"F Mantovani","year":"2019","unstructured":"Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26:199\u2013212.","journal-title":"Cell Death Differ"},{"key":"3880_CR41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc.2017.109","volume":"18","author":"VJN Bykov","year":"2018","unstructured":"Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89\u2013102.","journal-title":"Nat Rev Cancer"},{"key":"3880_CR42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nature02313","volume":"428","author":"H Rajagopalan","year":"2004","unstructured":"Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, et al. Inactivation of hCDC4 can cause chromosomal instability. Nature. 2004;428:77\u201381.","journal-title":"Nature"},{"key":"3880_CR43","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","volume":"169","author":"T Ishida","year":"2015","unstructured":"Ishida T, Jo T, Takemoto S, Suzumiya H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672\u201382.","journal-title":"Br J Haematol"},{"key":"3880_CR44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/bjh.18281","volume":"198","author":"T Shichijo","year":"2022","unstructured":"Shichijo T, Nosaka K, Tatetsu H, Higuchi Y, Endo S, Inoue Y, et al. Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma. Br J Haematol. 2022;198:983\u20137.","journal-title":"Br J Haematol"},{"key":"3880_CR45","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837\u201342.","journal-title":"J Clin Oncol"},{"key":"3880_CR46","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","volume":"108","author":"T Ishida","year":"2017","unstructured":"Ishida T, Utsunomiya A, Jo T, Yamamoto K, Kato K, Yoshida S, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies. Cancer Sci. 2017;108:2022\u20139.","journal-title":"Cancer Sci"},{"key":"3880_CR47","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3324\/haematol.2021.280352","volume":"107","author":"N Tanaka","year":"2022","unstructured":"Tanaka N, Mori S, Kiyotani K, Ota Y, Gotoh O, Kusumoto S, et al. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma. Haematologica. 2022;107:2418\u201331.","journal-title":"Haematologica"},{"key":"3880_CR48","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"3880_CR49","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","volume":"208","author":"G Fabbri","year":"2011","unstructured":"Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208:1389\u2013401.","journal-title":"J Exp Med"},{"key":"3880_CR50","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","volume":"27","author":"N Villamor","year":"2013","unstructured":"Villamor N, Conde L, Mart\u00ednez-Trillos A, Cazorla M, Navarro A, Bea S, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013;27:1100\u20136.","journal-title":"Leukemia"},{"key":"3880_CR51","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","volume":"119","author":"R Kridel","year":"2012","unstructured":"Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119:1963\u201371.","journal-title":"Blood"},{"key":"3880_CR52","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood.2021012386","volume":"139","author":"F Bonfiglio","year":"2022","unstructured":"Bonfiglio F, Bruscaggin A, Guidetti F, di Bergamo LT, Faderl M, Spina V, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139:732\u201347.","journal-title":"Blood"},{"key":"3880_CR53","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2005-12-4956","volume":"108","author":"S Breit","year":"2006","unstructured":"Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood. 2006;108:1151\u20137.","journal-title":"Blood"},{"key":"3880_CR54","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1182\/blood-2008-10-184069","volume":"113","author":"V Asnafi","year":"2009","unstructured":"Asnafi V, Buzyn A, Noir SL, Baleydier F, Simon A, Beldjord K, et al. NOTCH1\/ FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2009;113:3918\u201324.","journal-title":"Blood"},{"key":"3880_CR55","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","volume":"31","author":"A Trinquand","year":"2013","unstructured":"Trinquand A, Tanguy-Schmidt A, Abdelali RB, Lambert J, Beldjord K, Lenglin\u00e9 E, et al. Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013;31:4333\u201342.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03880-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03880-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03880-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:35:36Z","timestamp":1738254936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03880-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3880"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03880-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiromi Iwasaki received research funding from Kyowa Kirin Co., Ltd. and honoraria from AbbVie, AstraZeneca, Chugai, Ono, Takeda, Janssen, Sanofi, SymBio and Daiichi Sankyo Co., Ltd. Shigeru Kusumoto received research funding from Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd., and received honoraria from Chugai Pharmaceutical Co., Ltd. and Kyowa Kirin Co., Ltd. Nobuaki Nakano received honoraria from Novartis, Takeda pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Celgene, Otsuka Pharmatceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., and Asahi Kasei Pharma Co., Ltd., and received consulting fee from JIMRO. Kentaro Yonekura received honoraria from AbbVie, Amgen, Daiichi Sankyo Co., Ltd., Eisai, Eli Lilly Japan, Janssen Pharmaceuticals, Kaken Pharmaceutical, Kyowa Kirin Co., Ltd., Maruho, Meiji Seika Pharma, Minophagen Pharmaceutical, Mundipharma, Novartis, Otsuka Pharmaceutical, Sun Pharma Japan, Sanofi, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Japan. Youko Suehiro received honoraria from Chugai Pharmaceutical, Abbvie, Sanofi, Ono, Janssen Pharmaceutical, Genmab, Kyowa Kirin, Bristol-Myers, Meiji Seika Pharma, Nippon Shinyaku, and Nippon Kayaku, and received consulting fees from JIMRO. Shinsuke Iida received honoraria from Janssen, Bristol-Myers Squibb, Ono, Takeda, and Sanofi, and received research funding from Sanofi, Chugai, Ono, Takeda, Janssen, Bristol-Myers Squibb, Abbvie, Novartis, Amgen, Daiichi Sankyo, Otsuka, Celgene, Alexion and Glaxo-Smith-Klein. Atae Utsunomiya received honoraria from Meiji Seika Pharma Co., Ltd., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., and Bristol-Myers, and received consulting fees from HUYA Japan, JIMRO, Meiji Seika Pharma Co., Ltd. and Otsuka Medical Devices Co., Ltd. Ryuzo Ueda reports grants from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd. and other support from Sustainable Cell Therapeutics Co., Ltd. outside the submitted work. The other authors have no COI to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the institutional ethics committees of Nagoya City University Graduate School of Medical Sciences (Nagoya, Japan), Nagoya University Graduate School of Medicine (Nagoya, Japan), Oita Prefectural Hospital (Oita, Japan), Fukuoka University (Fukuoka, Japan), National Hospital Organization Kyushu Cancer Center (Fukuoka, Japan), National Hospital Organization Kyushu Medical Center (Fukuoka, Japan), and Imamura General Hospital (Kagoshima, Japan). All patients registered to the present study provided written informed consent before tumor sampling according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}